Metabolic and vascular features of dynamic contrast-enhanced breast magnetic resonance imaging and 15O-water positron emission tomography blood flow in breast cancer

被引:27
作者
Eby, Peter R. [1 ]
Partridge, Savannah C. [1 ]
White, Steven W. [1 ]
Doot, Robert K. [2 ,3 ]
Dunnwald, Lisa K. [2 ]
Schubert, Erin K. [2 ]
Kurland, Brenda F. [4 ]
Lehman, Constance D. [1 ]
Mankoff, David A. [1 ,2 ]
机构
[1] Univ Washington, Dept Radiol, Seattle, WA 98109 USA
[2] Univ Washington, Med Ctr, Div Nucl Med, Seattle, WA 98195 USA
[3] Univ Washington, Dept Bioengn, Seattle, WA 98195 USA
[4] Fred Hutchinson Canc Res Ctr, Div Clin Res, Seattle, WA 98109 USA
基金
美国国家卫生研究院;
关键词
breast cancers; MRI; enhancement kinetics; O-15-PET;
D O I
10.1016/j.acra.2008.03.019
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Rationale and Objectives. We sought to (1) describe associations between measures of tumor perfusion by dynamic contrast-enhanced breast magnetic resonance imaging (DCE-MRI), blood flow by O-15-water positron emission tomography (PET) and metabolism by F-18-fluorodeoxyglucose (F-18)-FDG PET and (2) improve our understanding of tumor enhancement on MRI through independent measures of tumor metabolism and blood flow. Materials and Methods. We performed a retrospective analysis of the existing PET and MRI databases from the Departments of Nuclear Medicine and Radiology. We identified patients with locally advanced breast cancer who underwent O-15-water/F-18-FDG PET within 1 month of clinical DCE-MRI between February 2004 and August 2006. The O-15-water PET blood flow and F-18-FDG metabolic rate and tissue transport constant (K-1) in the primary malignancy were calculated. DCE-MRI peak percent enhancement and peak signal enhancement ratio (SER) were measured for each tumor. Correlations and regression analysis of these variables were performed. Results. Fifteen patients with complete PET and DCE-MRI data were included in the analysis cohort. Peak SER correlated significantly with blood flow (r = 0.73. P = .002) and K-1 (r = 0.76, P = .001). However, peak SER did not correlate significantly with FDG metabolic rate (r = 0.44. P = .101). There were no significant correlations between peak percent enhancement and any of the PET parameters. Conclusions. Our findings suggest that tumor perfusion. represented by O-15-water PET blood flow, is an important factor in the MRI enhancement of locally advanced breast cancer. A lack of correlation of FDG metabolic rate with blood flow and DCE-MRI kinetics suggests that F-18-FDG PET provides complementary metabolic information independent of vascular factors.
引用
收藏
页码:1246 / 1254
页数:9
相关论文
共 52 条
  • [1] METABOLISM OF HUMAN GLIOMAS - ASSESSMENT WITH H-1 MR SPECTROSCOPY AND F-18 FLUORODEOXYGLUCOSE PET
    ALGER, JR
    FRANK, JA
    BIZZI, A
    FULHAM, MJ
    DESOUZA, BX
    DUHANEY, MO
    INSCOE, SW
    BLACK, JL
    VANZIJL, PCM
    MOONEN, CTW
    DICHIRO, G
    [J]. RADIOLOGY, 1990, 177 (03) : 633 - 641
  • [2] BEANEY RP, 1984, LANCET, V1, P131
  • [3] Diagnostic accuracy of mammography, clinical examination, US, and MR imaging in preoperative assessment of breast cancer
    Berg, WA
    Gutierrez, L
    NessAiver, MS
    Carter, WB
    Bhargavan, M
    Lewis, RS
    Ioffe, OB
    [J]. RADIOLOGY, 2004, 233 (03) : 830 - 849
  • [4] Can contrast-enhanced MR imaging predict survival in breast cancer?
    Boné, B
    Szabó, BK
    Perbeck, LG
    Veress, B
    Aspelin, P
    [J]. ACTA RADIOLOGICA, 2003, 44 (04) : 373 - 378
  • [5] Microcirculation and microvasculature in breast tumors: Pharmacokinetic analysis of dynamic MR image series
    Brix, G
    Kiessling, F
    Lucht, R
    Darai, S
    Wasser, K
    Delorme, S
    Griebel, J
    [J]. MAGNETIC RESONANCE IN MEDICINE, 2004, 52 (02) : 420 - 429
  • [6] Comparison of pharmacokinetic MRI and [18F] fluorodeoxyglucose PET in the diagnosis of breast cancer:: initial experience
    Brix, G
    Henze, M
    Knopp, MV
    Lucht, R
    Doll, J
    Junkermann, H
    Hawighorst, H
    Haberkorn, U
    [J]. EUROPEAN RADIOLOGY, 2001, 11 (10) : 2058 - 2070
  • [7] CHEN JH, 2007, CANCER, V112, P17
  • [8] Combined use of MRI and PET to monitor response and assess residual disease for locally advanced breast cancer treated with neoadjuvant chemotherapy
    Chen, XM
    Moore, MO
    Lehman, CD
    Mankoff, DA
    Lawton, TJ
    Peacock, S
    Schubert, EK
    Livingston, RB
    [J]. ACADEMIC RADIOLOGY, 2004, 11 (10) : 1115 - 1124
  • [9] Decrease in tumor apparent permeability-surface area product to a MRI macromolecular contrast medium following angiogenesis inhibition with correlations to cytotoxic drug accumulation
    Daldrup-Link, HE
    Okuhata, Y
    Wolfe, A
    Srivastav, S
    Oie, S
    Ferrara, N
    Cohen, RL
    Shames, DM
    Brasch, RC
    [J]. MICROCIRCULATION, 2004, 11 (05) : 387 - 396
  • [10] Esserman Laura, 1999, Breast J, V5, P13, DOI 10.1046/j.1524-4741.1999.005001013.x